Home > Publications database > Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years > print

001     1023535
005     20250204113808.0
024 7 _ |a 10.1001/jamanetworkopen.2023.52177
|2 doi
024 7 _ |a 10.34734/FZJ-2024-01741
|2 datacite_doi
024 7 _ |a 38236600
|2 pmid
024 7 _ |a WOS:001145711600006
|2 WOS
037 _ _ |a FZJ-2024-01741
082 _ _ |a 610
100 1 _ |a Jost, Stefanie T.
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years
260 _ _ |a Chicago, Ill.
|c 2024
|b American Medical Association
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1708688345_6976
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Importance: Deep brain stimulation of the subthalamic nucleus (STN-DBS) improves quality of life (QOL) in patients with advanced Parkinson disease (PD). However, controlled studies with more than 3 years of follow-up are lacking.Objective: To investigate the long-term effects of STN-DBS on QOL compared with standard-of-care medication (MED).Design, setting, and participants: In this prospective, observational, quasi-experimental, longitudinal nonrandomized controlled trial, 183 patients were screened for eligibility and 167 were enrolled from March 1, 2011, to May 31, 2017, at 3 European university centers. Propensity score matching for demographic and clinical characteristics was applied to 108 patients with PD (62 in the STN-DBS group and 46 in the MED group), resulting in a well-balanced, matched subcohort of 25 patients per group. Data analysis was performed from September 2022 to January 2023.Exposure: Treatment for PD of STN-DBS or MED.Main outcomes and measures: Assessments included Parkinson's Disease Questionnaire 8 (PDQ-8), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-activities of daily living (ADL) and motor complications, and levodopa-equivalent daily dose. Within-group longitudinal outcome changes, between-group differences, and correlations of change scores were analyzed.Results: The study population in the analysis included 108 patients (mean [SD] age, 63.7 [8.3] years; 66 [61.1%] male). At 5-year follow-up, PDQ-8 and ADL worsened only in the MED group (PDQ-8 change, -10.9; 95% CI, -19.0 to -2.7; P = .01; ADL change: -2.0; 95% CI, -3.1 to -0.8; P = .002), whereas both outcomes remained stable in the STN-DBS group (PDQ-8 change, -4.3; 95% CI, -13.2 to 4.7; P = .34; ADL change, -0.8; 95% CI, -2.5 to 1.0; P = .38). Changes in PDQ-8 and ADL correlated moderately (rs = .40, P = .008). Furthermore, STN-DBS outcomes were favorable for motor complications (median difference in change scores between STN-DBS and MED, -2.0; 95% CI, -4.0 to -1.0; P = .003), mobility (-1.0; 95% CI, -2.0 to 0; P = .03), and levodopa-equivalent daily dose reduction (-821.4; 95% CI, -1111.9 to -530.8; P < .001).Conclusions and relevance: This study provides evidence of differences in QOL outcomes at 5-year follow-up between STN-DBS (stable) and MED (worsened), mainly driven by the favorable effect of STN-DBS on mobility (class IIb evidence). The association between changes in QOL and ADL, but not motor impairment or complications, highlights the relative importance of ADL outcomes for long-term DBS assessments.Trial registration: German ClinicalTrials Registry: DRKS00006735.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Aloui, Salima
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Evans, Julian
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Ashkan, Keyoumars
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Sauerbier, Anna
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Rizos, Alexandra
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Petry-Schmelzer, Jan Niklas
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Gronostay, Alexandra
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Fink, Gereon R.
|0 P:(DE-Juel1)131720
|b 8
700 1 _ |a Visser-Vandewalle, Veerle
|b 9
700 1 _ |a Antonini, Angelo
|b 10
700 1 _ |a Silverdale, Monty
|b 11
700 1 _ |a Timmermann, Lars
|b 12
700 1 _ |a Martinez-Martin, Pablo
|b 13
700 1 _ |a Chaudhuri, K. Ray
|b 14
700 1 _ |a Dafsari, Haidar S.
|b 15
700 1 _ |a Martinez-Martin, Pablo
|b 16
700 1 _ |a Rodriguez-Blazquez , Carmen
|b 17
700 1 _ |a Chaudhuri, Ray
|b 18
700 1 _ |a Rizos, Alexandra
|b 19
700 1 _ |a Sauerbier, Anna
|b 20
700 1 _ |a Parry, Miriam
|b 21
700 1 _ |a Trivedi, Dhaval
|b 22
700 1 _ |a Martino, Davide
|b 23
700 1 _ |a Odin, Per
|b 24
700 1 _ |a Antonini, Angelo
|b 25
700 1 _ |a Stocchi, Fabrizio
|b 26
700 1 _ |a van Hilten, Jacobus J
|b 27
700 1 _ |a van Laar, Teus
|b 28
700 1 _ |a Falup-Pecurariu, Cristian
|b 29
700 1 _ |a Dietrichs, Espen
|b 30
700 1 _ |a Lyons, Kelly E.
|b 31
700 1 _ |a Weintraub, Dan
|b 32
700 1 _ |a Kurtis, Monica
|b 33
700 1 _ |a Serrano-Dueñas, Marcos
|b 34
700 1 _ |a Borges, Vanderci
|b 35
700 1 _ |a Behari, Madhuri
|b 36
700 1 _ |a Bhattacharya, Kalyan
|b 37
700 1 _ |a Kumar, Hrishikesh
|b 38
700 1 _ |a Singhal, Bhim
|b 39
700 1 _ |a Bhidayasiri, Roongroj
|b 40
700 1 _ |a Shen-Yang, Lim
|b 41
700 1 _ |a Gallardo, Marisol
|b 42
700 1 _ |a Abe, Kazuo
|b 43
700 1 _ |a Bostantjopoulou, Sevasti
|b 44
700 1 _ |a Martin Rabey, Jose
|b 45
700 1 _ |a Micheli, Federico
|b 46
700 1 _ |a Rodriguez-Violante, Mayela
|b 47
700 1 _ |a Riboldazzi, Giulio
|b 48
700 1 _ |a Catalan, Maria Jose
|b 49
700 1 _ |a Ellis, Cathy
|b 50
700 1 _ |a Bean, Lorna
|b 51
700 1 _ |a Kessel, Belinda
|b 52
700 1 _ |a Worth, Paul
|b 53
700 1 _ |a Shearing, Gemma
|b 54
700 1 _ |a Sophia, Rani
|b 55
700 1 _ |a Sharma, Jagdish
|b 56
700 1 _ |a Silverdale, Monty
|b 57
700 1 _ |a Pal, Suvankar
|b 58
700 1 _ |a Ashkan, Keyoumars
|b 59
700 1 _ |a Adler, Charles
|b 60
700 1 _ |a Barone, Paolo
|b 61
700 1 _ |a Brooks, David J.
|b 62
700 1 _ |a Brown, Richard
|b 63
700 1 _ |a Cantillon, Marc
|b 64
700 1 _ |a Carroll, Camille
|b 65
700 1 _ |a Coelho, Miguel
|b 66
700 1 _ |a Dafsari, Haidar S.
|b 67
700 1 _ |a Henriksen, Tove
|b 68
700 1 _ |a Hu, Michele
|b 69
700 1 _ |a Jenner, Peter
|b 70
700 1 _ |a Kramberger, Milica
|b 71
700 1 _ |a Kumar, Padma
|b 72
700 1 _ |a Kurtis, Mónica
|b 73
700 1 _ |a Lewis, Simon
|b 74
700 1 _ |a Litvan, Irene
|b 75
700 1 _ |a Lyons, Kelly
|b 76
700 1 _ |a Masellis, Mario
|b 77
700 1 _ |a Mochizuki, Hideki
|b 78
700 1 _ |a Morley, James F.
|b 79
700 1 _ |a Nirenberg, Melissa
|b 80
700 1 _ |a Pagonabarraga, Javier
|b 81
700 1 _ |a Panicker, Jalesh
|b 82
700 1 _ |a Pavese, Nicola
|b 83
700 1 _ |a Pekkonen, Eero
|b 84
700 1 _ |a Postuma, Ron
|b 85
700 1 _ |a Rosales, Raymond
|b 86
700 1 _ |a Schapira, Anthony
|b 87
700 1 _ |a Simuni, Tanya
|b 88
700 1 _ |a Subramanian, Indu
|b 89
700 1 _ |a Tagliati, Michele
|b 90
700 1 _ |a Timmermann, Lars
|b 91
700 1 _ |a Tinazzi, Michele
|b 92
700 1 _ |a Toledo, Jon
|b 93
700 1 _ |a Tsuboi, Yoshio
|b 94
700 1 _ |a Walker, Richard
|b 95
773 _ _ |a 10.1001/jamanetworkopen.2023.52177
|g Vol. 7, no. 1, p. e2352177 -
|0 PERI:(DE-600)2931249-8
|n 1
|p e2352177 -
|t JAMA network open
|v 7
|y 2024
|x 2574-3805
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/1023535/files/PDF.pdf
856 4 _ |y OpenAccess
|x icon
|u https://juser.fz-juelich.de/record/1023535/files/PDF.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://juser.fz-juelich.de/record/1023535/files/PDF.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://juser.fz-juelich.de/record/1023535/files/PDF.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://juser.fz-juelich.de/record/1023535/files/PDF.jpg?subformat=icon-640
909 C O |o oai:juser.fz-juelich.de:1023535
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-27
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-10-18T13:36:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-10-18T13:36:16Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-10-18T13:36:16Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-27
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JAMA NETW OPEN : 2022
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-09
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b JAMA NETW OPEN : 2022
|d 2024-12-09
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21